Harrow has completed its acquisition of TYRVAYA, adding a differentiated dry-eye treatment to its specialty ophthalmology platform. The transaction gives the company the first and only FDA-approved nasal spray for dry eye disease, according to the company announcement.

The strategic appeal is straightforward: TYRVAYA broadens Harrow’s ocular surface franchise beyond conventional eye-drop delivery. For patients and prescribers, its nasal-spray format creates a drop-free option in a category traditionally associated with administering medication directly to the eye.

A differentiated addition to the portfolio

TYRVAYA’s positioning is its clearest asset in this transaction. Rather than functioning as another eye-drop product, it is delivered as a nasal spray for dry eye disease. That distinction may give Harrow a more varied offering across the ocular surface market, while adding a product with a delivery method that stands apart from conventional treatments.

The FDA-approved designation is also significant. TYRVAYA is identified as the first and only FDA-approved nasal spray for dry eye disease, giving the product a specific regulatory and commercial identity within Harrow’s expanding ophthalmic portfolio. The acquisition therefore represents more than an incremental product addition: it adds a differentiated platform asset to the company’s ocular surface strategy.

Why investors may focus on the deal

For investors tracking mid-cap pharmaceutical consolidation, the transaction offers a clear example of a bolt-on acquisition aimed at expanding specialty-market reach. Harrow is using an acquired product to broaden its ophthalmology franchise, rather than relying solely on a single treatment format or therapeutic niche.

The deal may also draw attention from investors evaluating recurring-revenue opportunities in specialty pharmaceuticals. TYRVAYA’s inclusion in Harrow’s portfolio creates a new product-level lens for assessing the company’s future commercial strategy. However, the supplied announcement does not provide purchase-price, sales, or share-price data, so the acquisition’s financial contribution and valuation impact cannot be quantified here.

The key distinction: delivery format

Dry eye treatment is often associated with eye drops, making TYRVAYA’s nasal-spray delivery central to the investment narrative. A drop-free option could help differentiate Harrow’s offering and may broaden the ways patients and clinicians approach ocular surface disease. Whether that distinction translates into meaningful commercial momentum will depend on factors not detailed in the supplied information, including adoption and financial performance.

For now, the completed acquisition establishes a sharper strategic message: Harrow is expanding its specialty ophthalmology footprint with a product that combines FDA-approved status, a distinct administration route, and a direct connection to the ocular surface market.